BridgeBio Pharma GAAP EPS of -$1.00 misses by $0.33, revenue of $154.2M beats by $5.13M
Source: SeekingAlpha
2026-02-24 16:06:33 ET
More on BridgeBio Pharma
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia - Slideshow
- BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection
- BridgeBio rises after late-stage trial win for dwarfism therapy
- BridgeBio Pharma prices $550M convertible bond offering
Read the full article on Seeking Alpha
For further details see:
BridgeBio Pharma GAAP EPS of -$1.00 misses by $0.33, revenue of $154.2M beats by $5.13M
BridgeBio Pharma Inc.
NASDAQ: BBIO
BBIO Trading
-1.29% G/L:
$72.48 Last:
1,329,064 Volume:
$73.16 Open:
BBIO Latest News
BBIO Stock Data
$13,905,867,946
157,635,809
2.34%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
